Who is sponsoring NCT03686449?

NCT03686449 is sponsored by Assiut University.

What drugs are being tested in NCT03686449?

Interventions in NCT03686449: Non-cultured Autologous Keratinocyte Suspension, Adipose-Derived Stem cell-Keratinocyte Suspension, Split skin graft.

What condition does NCT03686449 study?

NCT03686449 studies Burn With Full-Thickness Skin Loss.

Is NCT03686449 still recruiting?

NCT03686449 is currently status unknown. Last updated 12 May 2020.

Last reviewed 2020-05-12 · How we verify

NCT03686449

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Autologous Keratinocyte Suspension Versus Adipose-Derived Stem Cell-Keratinocyte Suspension for Post-Burn Raw Area

Status unknown NA Last updated 12 May 2020

What this trial tests

NA trial testing Non-cultured Autologous Keratinocyte Suspension in Burn With Full-Thickness Skin Loss in 33 participants. Status unknown.

Timeline

1 November 2020

Primary endpoint
31 December 2020

31 May 2021

Quick facts

Lead sponsor	Assiut University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	1 November 2020
Primary completion	31 December 2020
Estimated completion	31 May 2021

Drugs / interventions tested

Non-cultured Autologous Keratinocyte Suspension
Adipose-Derived Stem cell-Keratinocyte Suspension
Split skin graft

Conditions studied

Burn With Full-Thickness Skin Loss — all drugs for Burn With Full-Thickness Skin Loss →

Sponsor

Assiut University

Who can join

18 and older, any sex, with Burn With Full-Thickness Skin Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study 1. Assess the efficiency of non-cultured autologous keratinocyte suspension in treating post-burn raw area. 2. Compare the results of keratinocyte suspension alone versus Adipose-derived mesenchymal stem cells-keratinocyte suspension in post-burn raw area.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03686449 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 12 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03686449.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing